Literature DB >> 16168484

LASIK in patients with rheumatic diseases: a pilot study.

Jorge L Alió1, Alberto Artola, José I Belda, Juan J Perez-Santonja, Gonzalo Muñoz, Jaime Javaloy, José L Rodríguez-Prats, Ahmed Galal.   

Abstract

PURPOSE: To investigate the safety of LASIK in patients with a known history of controlled rheumatic diseases.
DESIGN: Retrospective consecutive observational clinical study. PARTICIPANTS: Forty-two eyes (22 patients) known to have had a history of rheumatic diseases underwent LASIK. All patients had a history of controlled rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, scleroderma, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease, arthritis, or Behçet's disease.
METHODS: Assessments were made preoperatively and at 1, 3, and 6 months postoperatively and included visual acuity (VA), refraction, keratometric readings, slit-lamp biomicroscopy, and corneal topography. All the patients underwent LASIK. Postoperative treatment included a topical steroid-antibiotic combination. MAIN OUTCOME MEASURES: Visual acuity, refraction, keratometric readings, and slit-lamp biomicroscopy findings at 1, 3, and 6 months postoperatively.
RESULTS: LASIK was performed uneventfully on all patients. The mean pre-LASIK spherical equivalent (SE) was -5.39+/-2.25, and the sixth month postoperative SE was -0.15+/-0.38 diopters (D) (P<0.001). Uncorrected VA 6 months after the LASIK procedure was 20/25. Enhancement procedures were performed in 6 of 42 eyes (14.3%) at variable times after the primary procedure. Postoperative follow-up showed development of a moderate degree of dry eye syndrome in 4 eyes (9.5%). Corneal haze, melting, flap, or interface complications were not observed in any of the study eyes.
CONCLUSIONS: In this small series, we found good outcomes when correcting refractive errors using LASIK in selected patients with controlled rheumatic diseases. In this series, a favorable postoperative visual outcome was obtained with no operative or postoperative vision-threatening complications.

Entities:  

Mesh:

Year:  2005        PMID: 16168484     DOI: 10.1016/j.ophtha.2005.06.022

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

Review 1.  [Corneal refractive surgery despite systemic diseases?]

Authors:  A Frings; N Ardjomand; T Katz; S J Linke; J Steinberg
Journal:  Ophthalmologe       Date:  2019-07       Impact factor: 1.059

2.  Post-LASIK dry eye.

Authors:  Roni M Shtein
Journal:  Expert Rev Ophthalmol       Date:  2011-10

3.  Decreased central corneal thickness in ankylosing spondylitis.

Authors:  Huseyin Ortak; Ahmet Inanır; Selim Demir; Alper Uysal; Şafak Şahin; Mustafa Sağcan; Yalçın Önder; Sait Alim; Ayşe Kevser Demir
Journal:  Int Ophthalmol       Date:  2013-07-12       Impact factor: 2.031

4.  Laser in situ keratomileusis in patients with collagen vascular disease: a review of the literature.

Authors:  Rachel G Simpson; Majid Moshirfar; Jason N Edmonds; Steven M Christiansen; Nicholas Behunin
Journal:  Clin Ophthalmol       Date:  2012-11-05

5.  Necrotizing keratitis after laser refractive surgery in patients with inactive inflammatory bowel disease.

Authors:  Muhammad Aman-Ullah; Howard V Gimbel; Mona K Purba; John A van Westenbrugge
Journal:  Case Rep Ophthalmol       Date:  2012-02-04

6.  Evaluation of Objective Signs and Subjective Symptoms of Dry Eye Disease in Patients with Inflammatory Bowel Disease.

Authors:  Zsolt Barta; Levente Czompa; Aniko Rentka; Eva Zold; Judit Remenyik; Attila Biro; Rudolf Gesztelyi; Judit Zsuga; Peter Szodoray; Adam Kemeny-Beke
Journal:  Biomed Res Int       Date:  2019-01-08       Impact factor: 3.411

Review 7.  Refractive surgery in systemic and autoimmune disease.

Authors:  Majed AlKharashi; Kraig S Bower; Walter J Stark; Yassine J Daoud
Journal:  Middle East Afr J Ophthalmol       Date:  2014 Jan-Mar

8.  Peripheral Ulcerative Keratitis following Laser in situ Keratomileusis.

Authors:  Bryn M Burkholder; Irene C Kuo
Journal:  Case Rep Ophthalmol       Date:  2016-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.